Accepted Manuscript



Polyaspartoyl·L-arginine inhibits platelet aggregation through stimulation of NO release from endothelial cells

Zhiyu Tang, Ming Zhao, Changling Li, Yinye Wang, Shiqi Peng

PII: S0014-2999(08)00408-1
DOI: doi: 10.1016/j.ejphar.2008.04.012
Reference: EJP 65136

To appear in: *European Journal of Pharmacology*

Received date: 26 November 2007
Revised date: 15 March 2008
Accepted date: 1 April 2008

Please cite this article as: Tang, Zhiyu, Zhao, Ming, Li, Changling, Wang, Yinye, Peng, Shiqi, Polyaspartoyl·L-arginine inhibits platelet aggregation through stimulation of NO release from endothelial cells, *European Journal of Pharmacology* (2008), doi: 10.1016/j.ejphar.2008.04.012

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

1 **Polyaspartoyl·L-arginine inhibits platelet aggregation through**
2 **stimulation of NO release from endothelial cells**

3 Zhiyu Tang[a], Ming Zhao[b], Changling Li[a], Yinye Wang[a*], Shiqi Peng[b*]
4 *[a]Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences,*
5 *Peking University, Beijing 100083; [b]Beijing Key Laboratories of Hydrone and Peptides, Capital*
6 *University of Medical Sciences, Beijing 100069, China*
7
8
9
10
11 *Authors for correspondence
12 Yinye Wang
13 Department of Molecular and Cellular Pharmacology, School of Pharmaceutical
14 Sciences, Peking University.
15 Tel.: 86-10-8280-2652
16 Fax: 86-10-6201-5584
17 E-mail address: wangyinye@bjmu.edu.cn
18 Shiqi Peng
19 Beijing Key Laboratories of Hydrone and Peptides, Capital University of Medical
20 Sciences
21 Tel: 86-10-8391-1528
22 Fax: 86-10-8391-1533
23 E-mail: sqpeng@bjmu.edu.cn

ACCEPTED MANUSCRIPT

1 **Abstract**

2 Polyaspartoyl·L-arginine (PDR) is an inhibitor of platelet aggregation *ex vivo* but *in*
3 *vitro*. This study attempts to elucidate the target cell of PDR action and its action
4 mechanism. PDR (1.7-170μg/ml) significantly inhibited platelet aggregation *in vitro*
5 in the presence of rat aortic endothelial cells (RAEC), NO synthase inhibitor
6 N-nitro-Larginine methyl ester (L-NAME) inhibited this effect, but it was ineffective
7 in the RAEC absence. Correspondingly, PDR increased NO level in the supernatants
8 of the platelet reactants in RAEC presence, but failed to influence NO level in RAEC
9 absence, and these effects of PDR were more potent than those of L-arginine.
10 Furthermore, PDR markedly elevated the intracellular level of L-arginine, and it
11 (17-170μg/ml) also augmented L-citrulline level in RAEC, argininosuccinate lyase
12 (ASL) inhibitor succinate enhanced its effect on L-citrulline but L-NAME weakened
13 it. 170μg/ml of PDR slightly increased the L-aspartate level in RAEC, and succinate
14 enhanced this effect. However L-arginine, L-aspartate or the combination of
15 L-arginine and L-aspartate failed to change levels of these amino acids. In addition,
16 PDR (170μg/ml) stimulated the expression of argininosuccinate synthetase (ASS)
17 protein. In conclusion, the endothelial cell is direct target cell of PDR's action; PDR
18 facilitates the entry of L-arginine by serving as a carrier of L-arginine into RAEC; it
19 also supplies aspartic acid and stimulates ASS expression, and then enhances the
20 intracellular citrulline–NO cycle, thus increases the availability of L-arginine and NO
21 synthesis. Therefore the effect of PDR on platelet aggregation is primarily attributed
22 to its stimulation of NO synthesis in endothelial cells; PDR may be a better

ACCEPTED MANUSCRIPT

1 cardiovascular protective agent than L-arginine.

2 *Keywords:* Polyaspartoyl·L-arginine; platelet aggregation; rat aortic endothelial cell;
3 nitric oxide; L-arginine; argininosuccinate synthetase; citrulline–NO cycle

4

5 **1. Introduction**

6 Platelet activation and aggregation play a key role in the pathogenesis of
7 thrombosis (Fitzgerald et al., 1986), which is directly associated with endothelial
8 function. Adherence of platelets to a defective endothelial cell monolayer, at the site
9 of injury, causes the release of potent vasoconstricting agonists such as thromboxane
10 A_2 and serotonin from platelets activated with sub-endothelial stimuli, including
11 collagen. To prevent these adverse effects, endothelial cells physiologically release
12 vasodilatory and anti-aggregatory agents, e.g., nitric oxide (NO) and prostacyclin
13 (Radomski et al., 1987; Az-ma et al., 1995). Platelets per se also produce NO
14 (Radomski et al., 1990). NO is known to attenuate platelet activation (Brune et al.,
15 1998; Mellgren et al., 1998) and inhibit platelet aggregation *in vitro* (Kurata et al.
16 1997) and *ex vivo* (Cheung et al., 1998). Studies have shown that endothelium-derived
17 NO inhibits platelet adhesion to endothelial cells (Radomski et al., 1993), and clot
18 formation in thromboelastography studies(Dambisya et al., 1996).

19 L-arginine, the sole physiological precursor, provides a guanidino nitrogen group
20 for NO synthesis through nitric oxide synthase (NOS) (Ignarro et al., 1987); it inhibits
21 platelet aggregation through platelet nitric oxide synthesis (Marietta et al., 1997). The
22 arginine–NO pathway of the endothelial cell is involved in the regulation of platelet

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT

1 function. In endothelial cells, there may be a separate pool of L-arginine directed to
2 endothelial NOS (eNOS), the formation of NO from L-arginine is dependent upon an
3 adequate and continuous supply of L-arginine (Ahlers et al., 2004). Intracellular
4 L-arginine can be obtained from exogenous sources via cationic amino acid
5 transporter or by endogenous synthesis. L-citrulline, which is formed from L-arginine
6 by the NOS reaction, can be recycled into L-arginine through the citrulline–NO cycle.
7 In the presence of L-aspartate, this recycling is accomplished by the successive
8 actions of argininosuccinate synthetase (ASS) and argininosuccinate lyase (ASL)
9 (Hattori et al., 1994; Hecker 1990). It has been demonstrated that the citrulline–NO
10 cycle may help to maintain a sufficient intracellular concentration of L-arginine for
11 NO generation (Wu et al., 1993; Hecker et al., 1990). ASS, the rate-limiting enzyme
12 of the citrulline–NO cycle, has been found to be co-localized with eNOS in the
13 caveolae of endothelial cells. Therefore, it is hypothesized that the regulation of ASS
14 activity can manipulate NO synthesis via eNOS (Flam et al., 2001).
15 Polyaspartoyl·L-arginine (PDR), a synthesized L-arginine residue-rich compound
16 with polyaspartate as the supporting molecular main chain, was recently reported to
17 inhibit platelet aggregation *ex vivo* (Wang et al., 2004) but not *in vitro*(unpublished
18 data), and reduced arterial thrombosis *in vivo* (Tang et al., 2003). Based on its
19 behavior on platelet aggregation, the effects of PDR are most likely mediated by
20 certain endogenous factors. This study attempted to define the target cell of PDR
21 action and to explain its inhibition of platelet aggregation and anti-thrombotic effect
22 by investigating (1) the influence of endothelial cells on the PDR's effect on platelet

ACCEPTED MANUSCRIPT

1 aggregation *in vitro*, (2) the effect of PDR on NO level in platelet reaction supernatant
2 with or without rat aortic endothelial cells (RAEC), (3) the effects of PDR on
3 intracellular concentration of L-arginine and related amino acids in RAEC, (4) the
4 influence of some related enzymes on PDR's effects .
5

6 ## 2. Materials and Methods

7

8 ### *2.1 Materials*

9

10 PDR was synthesized by our colleagues at The Laboratories of Hydrone and
11 Peptides in Capital University of Medical Sciences, and the light brown powder
12 (purity is 98.8%) was dissolved in normal saline before use. Trypsin, EDTA-Na_2 and
13 thrombin were Sigma Co. products; thrombin dissolved in normal saline before use.
14 Medium 1640 was a GIBCO product; fetal calf serum was obtained from Tianjin
15 Caihui Biochemical Product Factory; Penicillin G was a product of North China
16 Pharmaceutical Corporation; Streptomycin was obtained from Dalian Meiluoda
17 Pharmaceutical Factory; Cell lysis buffer was the product of Beyotime Biotechnology,
18 China. Other chemicals and agents were obtained in the commercially available
19 quality. Collagen in rat-tail was self-prepared as previously described (Wang et al.,
20 2004). Sprague-Dawley rats were obtained from the Experimental Animal Center of
21 Peking University.
22

ACCEPTED MANUSCRIPT

1 *2.2 Endothelial Cell Culture*

2

3 Endothelial cells were obtained from rat aortas and subcultured as described by
4 others (Centra et al., 1992). Briefly, Male Sprague–Dawley rats weighing 180–200 g
5 were anesthetized with an overdose of sodium pentobarbital and the abdominal aortas
6 of rats were rapidly removed and collected in medium 1640. Surrounding fat and
7 connective tissue were cleaned off, and then aortas were cut longitudinally. The aortic
8 endothelium were scraped with vertical ophthalmic forceps and the cells were
9 collected into a T25 polystyrene flask, then cultured initially in medium 1640
10 containing 20% new born calf serum and 100U/mL penicillin-100μg/ml streptomycin
11 at 37℃ in a 5% CO_2 atmosphere. The endothelial cells were allowed to grow
12 undisturbed for 3-4 days and thereafter the media was changed once every 2 days for
13 a total culturing period of 8 to 10 days. All monolayer were initially identified as
14 endothelial cells by phase-contrast microscopy. The cell culture purity (98%) was
15 assessed by staining for factor VIII antigen, as previously described (Jaffe et al.,
16 1973). Confluent cells were passaged by trypsinization in D-Hank's containing 0.05%
17 trypsin and 0.02% EDTA. Passage 4~6 cells were used in experiments. The
18 incubation medium was changed to serum-free medium 1640 at 24 h before
19 experiment.

20

21 *2.3 Platelet Aggregation Activity in vitro*

22

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT

1 *2.3.1 Preparation of washed platelets*

2 After an overnight fasting, the blood from normal rabbits was collected in a plastic
3 syringe containing 1/10 volume of 2% EDTA Na_2. Platelet-rich plasma was prepared
4 by centrifuging the blood samples at room temperature for 10 minutes at 200×g. the
5 washed platelets were prepared as the reported (Mikashima et al., 1987). Shortly, the
6 upper layer was collected and diluted with the same volume of platelet-washed buffer
7 and centrifuged at 1200×g for 10 min. The platelet pellets were then re-suspended and
8 washed three times. The final pellets were suspended with platelet diluted buffer
9 (1.17mM $CaCl_2$, 0.1% BSA in the platelet washed buffer) and diluted to 2×10^8
10 platelets/ml, and stood at room temperature for use.

11

12 *2.3.2 Pre-treatment of endothelial cells and platelets*

13

14 The influence of endothelial cell on PDR's effect on platelet aggregation was
15 examined as previously described (Igawa et al., 1990; Macdonald et al., 1988) with
16 modification. In brief, monolayer RAEC in flasks were trypsinized and prepared into
17 2×10^6/ml of cell suspension with 1% serum-containing medium 1640 then
18 pre-incubated with or without 100μM of N-nitro-Larginine methyl ester (L-NAME)
19 for 24 h. Dispensed 50μl cell culture medium, with or without endothelial cells, into
20 each siliconized aggregate cuvettes, then incubated at 37℃ under an atmosphere of
21 5% CO_2. After a 4 h recovery incubation, the cuvettes were treated with NS or
22 NS-containing agents (10 μg/ml of SNP, 170 μg/ml of L-Arginine, 1.7, 17 or 170

ACCEPTED MANUSCRIPT

1 μg/ml of PDR) and stood for 30 min at 37℃, then 200μl of platelet suspension was
2 then added into the cuvettes for platelet aggregation study.
3
4 *2.3.3 Platelet aggregation assay*
5
6 Platelet aggregation was performed on Chrono-log model 490 optical aggregometer
7 as Born's method. The aggregation was induced using 0.2IU/mL of thrombin. The
8 percent inhibition of platelet aggregation was calculated according to the following
9 formula: Inhibition (%) = $(A - A_1)/A \times 100\%$, where A was the maximum light
10 transmission of the vehicle group and A_1 was the maximum light transmission of each
11 sample after treatment with the agents. After ending the test, the reaction mediums
12 were centrifuged at 3000×g and the supernatant were immediately frozen and stored
13 at -20℃ to determine the concentration of NO.
14
15 *2.3.4 The determination of NO in the supernatant of platelet reaction mixtures*
16
17 A sensitive fluorometric method for nitrite determination was used as previously
18 described (Misko et al., 1993) to measure NO level in samples with minor
19 modifications. Briefly, 100μl of samples were placed into white opaque 96-well plates
20 after thawing and centrifugation, then 10μl of freshly prepared
21 2,3-diaminonaphthalene (0.05 mg/ml in 0.62 N HCl) was added and mixed
22 immediately, then incubated for 15 min at room temperature. The reaction was

ACCEPTED MANUSCRIPT

terminated with 5μl of 2.8 M NaOH and the plate was read on a Cary Eclipse luminescence spectrometer (excitation 360 nm, emission 440 nm). Standard curves were made daily with sodium nitrite, ranging from 0.04~10 μM, in Krebs-Henseleit buffer.

2.4 Intracellular amino acids' level in RAEC

2.4.1 Sample preparation

Confluent 4-6 passage endothelial cells, seeded into 6-well plates with 2×10^4 cells/ml, were used for the experiments. Each well was rinsed with serum free medium and equilibrated in the incubator (37) for 30 min with 2ml of Hank's balanced salt solution as other method (Su et al., 1995). Then three sets of experiments were performed: in set 1 the cells were only treated with PDR and other agents; in set 2 the cells were pretreated with succinate (3 mM) for 30 min at 37 prior to PDR and other agents treatment; and in set 3 the cells were treated with L-NAME (100 μM) for 24 h at 37 prior to PDR and other agents treatment. The cells of each set were all treated with vehicle, L-arginine, L-aspartate, L-arginine plus L-aspartate or PDR for 30 min at 37 respectively, accompanied by A23187 (final concentration 1.0μM) to observe the influences of PDR on eNOS which is Ca^{2+} dependent. Succinate and L-NAME were applied to observe the influence of PDR on eNOS and the citrulline-NO cycle, respectively. The cell incubations were terminated

ACCEPTED MANUSCRIPT

1 by ice bath, the supernatants were immediately frozen and stored at -20 to determine
2 the concentration of NO, its determination was performed as mentioned above (*in*
3 *2.3.4*). To measure the intracellular AA levels, the monolayer cells were rinsed at
4 least 5 times with cold PBS, collected with 200μl of 96% methanol and were exposed
5 to 3 cycles of freezing and thawing to lyse, then centrifuged at 10,000×g for 5 min at
6 4 . 100μl of the supernatant was blown dry with nitrogen gas, then stored at -20 in
7 order to measure the concentration of L-arginine and other amino acids. The cell
8 residues were lysed again in lysis buffer and the supernatant was collected and stored
9 at -20 for the measurement of protein after centrifuged at 10,000×g at 4 for 5min.
10 Protein concentrations were determined by Bradford method (Bradford, 1976) and
11 used to normalize intracellular amino acid values.
12
13 *2.4.2 Intracellular amino acids detection*
14
15 Nitrogen gas-dried samples were thawed temporarily and the levels of L-arginine,
16 L-citrulline and L-aspartate were determined by high-performance liquid
17 chromatography according to published methods (Contreras et al., 1997; Sobrevia et
18 al., 1998). Briefly, o-phthalaldehyde (OPA) solution was freshly prepared by
19 dissolving 10 mg of OPA in 0.5 ml of methanol, and then 10μl β-mercaptoethanol and
20 2ml sodium tetraborate buffer (0.1 M, pH 9.4) were added. The test samples were
21 dissolved in 200μl mobile phase B, as mentioned below, containing 10μM GABA as
22 an internal standard. 30 μl of the sample was mixed with 30μl OPA solution. After

ACCEPTED MANUSCRIPT

1 exactly 2 min, 20 μl of the mixture was immediately injected onto the spherisorb C18
2 ODS column(Waters 4.6×250mm i.d.5μm) fitted with a security guard C18 ODS
3 column (Phenomenex 4.6×30mm i.d.5μm). Mobile phases consisting of 50 mM
4 sodium acetate (pH=6.8): methanol: THF (Mobile phase A= 82:17:1; Mobile phase
5 B= 22:77:1) were filtered through a 0.2μm filter. Each component of the mobile phase
6 was degassed ultrasonically before use. The following gradient systems were used:
7 0-1 min, isocratic with 5% mobile phase B; 1–8 min, linear gradient to 15% B; 8–14
8 min, linear gradient to 30% B; 14–19 min, linear gradient to 40% B; 19–20 min,
9 increasing to 100% B; 20–34 min, isocratic with 100% B; linear reverse gradient to
10 5% B at 35 min. Between two consecutive samples, a 10 min wash-out was carried
11 out with 5% B and then re-equilibrated. All separations were performed at 37 and at
12 a flow-rate of 1.0 ml/ml using Agilent-1100 series HPLC. Fluorescent detection was
13 accomplished by use of an excitation wavelength of 338 nm with emission detection
14 at 450 nm. Amino acid concentrations were calculated from the peak areas by
15 reference to the area of the internal standard GABA and normalized by protein
16 contents. The limit of detection for all the amino acids measured was within the range
17 of 10 pM.
18
19 *2.5 Western Blot Analysis of argininosuccinate synthase*
20
21 The 4-6 passage rat aortic endothelial cells were seeded into 6-well plates with
22 2×10^5 cells/ml and cultured until confluence. Endothelial cells were treated with

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT

vehicle, 1.7, 17 or 170 μg/ml of PDR for 24h, respectively. After removal of media, cells were washed twice with ice-cold PBS, then lysed using cell lysis buffer. The lysates were collected by scraping from the plates and centrifuged at 10,000×g at 4 for 5min, and the supernatants were stored at -20 for electrophoresis. For obtaining ASS protein control, 0.06 g of fresh rat liver was homogenized in 2 ml of cell lysis buffer and centrifuged at 10,000 *g* for 5 min at 4 and the supernatant was then collected for electrophoresis. Western blot was performed according to the procedure previously described (Towbin et al., 1979). Briefly, protein extracts were separated by electrophoresis (50 μg protein per lane) on a 12% SDS-polyacrylamide gel and transferred onto nitrocellulose transfer membranes (Osmonics, USA) at 0.8mA/cm^2 for 2h. Nonspecific activity was blocked in 5% fat-free milk in TBST(10mM Tris-HCl, pH7.5, 150mM NaCl, 0.1%Tween-20) for 1h at room temperature. The membrane was then probed with a primary polyclonal mouse anti-ASS (1:1000) (Santa Cruz Biotechnology, USA) by incubation overnight at 4 , then washed in Tris buffer saline Tween (TBST, 50 mmol/L Tris/HCl, 150 mmol/L NaCl, 1% v/v Tween 20, pH 7.4), and incubated for 1 h in TBST/0.2% BSA containing horseradish peroxidase-conjugated goat anti-mouse antibody (1:200). Detection was performed by enhanced chemiluminescence (Santa Cruz Biotechnology, USA) and bands were then quantified by scanning densitometry (THERMAL IMAGING SYSTEM FTI-500, Pharmacia Biotech). Protein concentrations were determined by Bradford method. β-actin of rat aortic endothelial cells was used as a housekeeping protein, and determined following the same procedure mentioned above using a specific anti-actin

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT

1 mouse monoclonal antibody (1:1000) (Sigma-Aldrich, Madrid, Spain) and the
2 horseradish peroxidase-conjugated goat anti-mouse antibody(1:200).
3
4 *2.6 Statistical analysis*
5
6 The results are expressed as mean±S.D.. The difference between the treated
7 groups and the control group was analyzed by Dunnet *t*- test. $P<0.05$ was considered
8 to be a significant difference.
9
10 **3. Results**
11
12 *3.1 Effect on platelet aggregation and NO synthesis in vitro*
13
14 In washed rabbit platelets, PDR at the concentration of 1.7 ~ 170 μg/ml did not
15 influence the platelet aggregation induced by thrombin and the NO level of the
16 supernatant of reaction mixtures in the absence of RAEC, whereas in the presence of
17 RAEC PDR at the same concentration range significantly inhibited the platelet
18 aggregation and increased the NO level in the supernatant of reaction mixtures, the
19 inhibition rates (%) on platelet aggregation for vehicle, 170 μg/ml of L-Arginine, 1.7,
20 17, 170 μg/ml of PDR treated group were 5.3 ±14.3, 34.2 ±9.9, 34.6 ±11.8, 50.4 ±10.1,
21 65.3 ±9.2, respectively. Meanwhile, the NO levels (expressed by the concentration of
22 nitrite) for vehicle, 170 μg/ml of L-Arg, 1.7, 17, 170 μg/ml of PDR treated group were

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT

1 43.9±15.4nM, 90.8±15.6nM, 108.2±13.4nM, 125.9±16.2 nM, 145.7±19.1 nM,
2 respectively. However, L-NAME (100mM) markedly inhibited the effects on platelet
3 aggregation and NO levels of these agents but SNP. The effects of L-arginine
4 (170μg/ml) on platelet aggregation and NO level were weaker than that of equal
5 concentration of PDR. As expected, 10 μg/ml of SNP, a NO donor, significantly
6 inhibited the platelet aggregation and enhanced the NO level of the supernatant of
7 reaction mixture, L-NAME failed to influence its effects (Table 1).
8
9 *3.2 Effects of PDR on intracellular amino acid Levels*
10
11 The intracellular contents of L-arginine, L-citrulliune and L-aspartate are exhibited
12 in figure 1. L-arginine, L-citrulliune and L-aspartate levels were expressed based upon
13 their mean values of vehicle in set 1 which was set at 100%. The intracellular contents
14 of L-arginine, L-citrulliune and L-aspartate were not significantly changed in the cells
15 treated by L-arginine, L-aspartate or the combinatin of L-arginine and L-aspartate
16 which was designed as the same proportion based on their contents in PDR. However
17 1.7, 17, 170 μg/ml of PDR significantly increased intracellular L-arginine level, which
18 were 1.97 fold, 2.25 fold, 2.91 fold of vehicle control, respectively. Similarly PDR
19 also evidently increased the level of intracellular L-citrulline, and its high
20 concentration slightly increased the intracellular L-aspartate level. The Citulline-NO
21 cycle inhibitor succinate did not influence the effect of PDR on intracellular
22 L-arginine and L-citrulline levels, but markedly increased its effect on the

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT

1 intracellular L-aspartate level. NOS inhibitor L-NAME, significantly weakened the
2 effect of PDR on the intracellular L-citrulline level.
3
4 *3.3 Effect of PDR on NO release from RAEC*
5
6 PDR increased NO level in the culture medium of RAEC in a concentration
7 dependent manner, 170 μg/ml of it showed a significant increase. Both the
8 NO-citrulline cycle inhibitor succinate and the NOS inhibitor, L-NAME, evidently
9 attenuated the effect of PDR on the release of NO (Figure 2).
10
11 *3.4 Effect of PDR on argininosuccinate synthase protein expression*
12
13 Western blot analysis using a polyclonal antibody against argininosuccinate
14 synthetase to detect argininosuccinate synthase protein level. Samples containing ASS
15 protein from rat liver tissue were used as a positive control according to another study
16 (Xie et al., 1997) and a marked band corresponding to ASS was detected which
17 corresponded to the molecular mass of one of the identical subunits of the tetrameric
18 ASS (45.4 kDa, as calculated from the amino acid composition). The cells treated by
19 PDR exhibited a concentration dependent increase on the ASS protein level. 1.7~17
20 μg/ml of PDR showed a tendency to increase the ASS protein level, 170 μg/ml of
21 PDR increased the ASS level significantly (Figure 3).
22

ACCEPTED MANUSCRIPT

1 **4. Discussion**

2

3 Since Furchgott and Zawadski first suggested the existence of endothelium-derived
4 relaxing factor (Furchgott et al., 1980), a large number of experimental studies have
5 proven the important role that NO plays in the function of the cardiovascular system.
6 L-arginine, the sole physiological precursor of NO, has a beneficial effect on
7 endothelium dependent vaso-reactivity, as well as on the interaction between the
8 vascular wall, platelets and leucocytes. Therefore, individuals with risk factors for
9 atherosclerosis and patients with coronary artery disease or heart failure could benefit
10 from therapy with L-arginine (Goumas et al., 2001).
11 PDR, an L-arginine residue-rich compound, has been reported to inhibit platelet
12 aggregation *ex vivo* in rabbits or rats (Wang et al., 2004) and prevent arterial
13 thrombosis in rats with raising NO level in serum (Tang et al., 2003). It did not,
14 however, inhibit platelet aggregation *in vitro* (unpublished data). This study
15 investigated the influences of PDR on platelet aggregation and on NO release *in vitro*
16 in the presence and in the absence of RAEC. The results in this study showed that
17 only when RAEC existed PDR inhibited platelet aggregation and increased NO
18 synthesis, it is indicated that the endothelial cell is the intermediary target of PDR and
19 the primary action of PDR is on endothelial cells but not on platelets. These effects of
20 PDR were blocked or attenuated by L-NAME, suggesting its role of anti-platelet
21 aggregation is attributed to its stimulating eNOS to enhance NO synthesis and release.

ACCEPTED MANUSCRIPT

1 L-arginine was described to inhibit platelet aggregation *in vitro* at high
2 concentration (Anfossi et al., 1999), in this study PDR up to 170μg/ml did not inhibit
3 platelet aggregation，but 170μg/ml of L-arginine exhibited somewhat inhibitory
4 effects in the absence of endothelial cells *in vitro*. However, in the presence of
5 endothelial cells, PDR displayed a more potent inhibitory effect than L-arginine,
6 suggested that the target of these two agents is slightly different, namely PDR only
7 targets endothelial cells but L-arginine targets both platelets and endothelial cells.
8 In this study ASL inhibitor succinate evidently blocked PDR's effect on NO release
9 in RAEC, indicating that PDR participates in the NO-citrulline cycle; NOS inhibitor
10 L-NAME displayed more potent inhibitory effects on NO synthesis of PDR,
11 suggesting the effect of PDR is primarily dependent on NOS.
12 To explore the details of PDR's effect on increasing the NO level, the levels of
13 L-arginine, L-citrulline or L-aspartate in endothelial cells were determined. We failed
14 to detect PDR's peak in RAEC extracts with HPLC, denoting that the entire molecule
15 of PDR may not be able to enter into endothelial cells. The facts that levels of
16 L-arginine and L-citrulline in RAEC were significantly raised by PDR, but were not
17 changed by other agents such as L-arginine, L-aspartate or the combination of
18 L-arginine and L-aspartate, suggested that free L-arginine or L-aspartate may not be
19 easily taken in by endothelial cells, but that polyaspartoyl acid, acting as a carrier,
20 may facilitate the uptake of L-arginine.
21 Several factors, like the intracellular compartmentalization of eNOS, L-arginine's
22 uptake system and the multi-purposes of L-arginine, limit the intracellular L-arginine

ACCEPTED MANUSCRIPT

1 availability for eNOS *in vivo.* Accordingly L-arginine's oral or intravenous infusion
2 dose that produced beneficial effects in the cardiovascular system was quite high, at a
3 range of 6-30 g/day (Goumas et al., 2001; Kanno et al., 1992). The daily doses of
4 L-arginine utilized in these studies exceeded the physiological uptake by 3-8 times
5 (Visek., 1986). Based on this study, PDR may provide an easier absorbed and higher
6 available L-arginine for eNOS compared with natural L-arginine, so the NO
7 concentration produced by PDR on platelet aggregation is much higher than that of
8 L-arginine.
9 Acting as the carrier molecule, containing L-arginine and L-aspartate components,
10 PDR may improve the availability of L-arginine not only by providing the L-arginine
11 component, but also by providing the L-aspartate component. This study showed that
12 PDR slightly increased the intracellular aspartic acid level and the increase was
13 enhanced when the citrulline–NO cycle was blocked by succinate, but other agents
14 did not change the L-aspartate level in the presence of succinate (Fig. 1), indicating
15 that the L-aspartate from PDR also participates in the citrulline-NO cycle with
16 L-arginine, thus stimulating the recycle of L-arginine.
17 ASS was first identified as the rate-limiting enzyme of the urea cycle in the liver 56
18 years ago (Ratner et al., 1951) and has more recently been recognized as a
19 rate-limiting enzyme in the citrulline–NO cycle (Xie et al., 1997). It catalyses the
20 reversible ATP-dependent condensation of citrulline with aspartate to form
21 argininosuccinate, which is the immediate precursor of L-arginine, leading to the
22 synthesis of NO in endothelial cells (Husson et al., 2003). In this study, PDR in

ACCEPTED MANUSCRIPT

1 170μg/ml significantly increased the expression of ASS in RAEC (Fig. 5), which also
2 enhanced the citrulline–NO cycle and contributed to the increase of synthesis of NO.
3 In conclusion, this study demonstrated that the endothelial cell is the direct target
4 cell of PDR's action on platelet aggregation; PDR facilitates the entry of L-arginine
5 by serving as a carrier molecule of L-arginine into RAEC; it also supplies aspartic
6 acid and stimulates ASS expression which then enhances the intracellular
7 citrulline–NO cycle, leading to an increase in the availability of L-arginine and NO
8 synthesis. The inhibitory effect of PDR on platelet aggregation is primarily attributed
9 to its stimulation of NO synthesis in endothelial cells; PDR may be a much better
10 cardiovascular protective agent than L-arginine.
11
12 **Acknowledgements**
13 This work was supported by National new drug developed funds; National Economy
14 and Trade Ministry Funds; and North China Pharmaceutical Groups New Drug R & D
15 funds.
16
17 **References**
18 Ahlers, B.A., Parnell, M.M., Chin-Dusting, J.P., Kaye, D.M., 2004. An age-related
19 decline in endothelial function is not associated with alterations in L-arginine
20 transport in humans. J. Hypertens. 22, 321-327.
21 Anfossi, G., Russo, I., Massucco, P., Mattiello, L., Perna, Paolo., Tassone, F.,
22 Trovati, M., 1999. l-Arginine Modulates Aggregation and Intracellular Cyclic

ACCEPTED MANUSCRIPT

1 39,59-Guanosine Monophosphate Levels in Human Platelets: Direct Effect and
2 Interplay with Antioxidative Thiol Agent. Thromb. Res. 94, 307-316.
3 Az-ma, T., Hardian., Yuge, O., 1995. Inhibitory effect of lidocaine on cultured porcine
4 aortic endothelial cell-dependent antiaggregation of platelets. Anesthesiology. 83,
5 374-381.
6 Bradford, M.M., 1976.A rapid and sensitive method for the quantitation of microgram
7 quantities of protein utilizing the principle of protein-dye binding. Anal.
8 Biochem. 72, 248-254
9 Brune, B., Hanstein, K., 1998. Rapid reversibility of nitric oxide induced platelet
10 inhibition. Thromb. Res. 90, 83-91.
11 Centra, M., Ratych, R.E., Cao, G.L., Li, J., Williams, E., Taylor, R.M., Rosen, G.M.,
12 1992. Culture of bovine pulmonary artery endothelial cells on Gelfoam blocks.
13 FASEB J. 6, 3117-3121.
14 Contreras, R., Fuentes, O., Mann, G.E., Sobrevia, L., 1997. Diabetes and
15 insulin-induced stimulation of L-arginine transport and nitric oxide synthesis in
16 rabbit isolated gastric glands. J. Physiol. 498, 787-796.
17 Dambisya, Y.M., Lee, T.L., 1996. A thromboelastography study on the *in vitro* effects
18 of L-arginine and L-NG-nitro arginine methyl ester on human whole blood
19 coagulation and fibrinolysis. Blood Coagul. Fibrinolysis.7, 678-683.
20 Cheung, P.Y., Salas, E., Etches, P.C., Phillipos, E., Schulz, R., Radomski, M.W., 1998.
21 Inhaled nitric oxide and inhibition of platelet aggregation in critically ill neonates.
22 Lancet 351, 1181-1182.

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT

1 Fitzgerald, D.J., Roy, L., Catella, F., FitzGerald, G.A., 1986. Platelet activation in
2 unstable coronary disease. N. Engl. J. Med. 315, 983-989.
3 Flam, B.R., Hartmann, P.J., Harrell-Booth, M., Solomonson, L.P., Eichler, D.C., 2001.
4 Caveolar localization of arginine regeneration enzymes, argininosuccinate
5 synthase, and lyase, with endothelial nitric oxide synthase. *Nitric Oxide* **5**,
6 187-197.
7 Furchgott, R.F., Zawadzki, J.V., 1980. The obligatory role of endothelial cells in the
8 relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373-376.
9 Goumas, G., Tentolouris, C., Tousoulis, D., Stefanadis, C., Toutouzas, P., 2001.
10 Therapeutic modification of the L-arginine-eNOS pathway in cardiovascular
11 diseases. Atherosclerosis 154, 255-267.
12 Hattori, Y., Campbell, E.B., Gross, S.S., 1994. Argininosuccinate synthetase mRNA
13 and activity are induced by immunostimulants in vascular smooth muscle. Role in
14 the regeneration or arginine for nitric oxide synthesis. J. Biol. Chem. 269,
15 9405-9408.
16 Hecker, M., Sessa, W.C., Harris, H.J., Anggard, E.E., Vane, J.R., 1990. The
17 metabolism of L-arginine and its significance for the biosynthesis of
18 endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline
19 to L-arginine. Proc. Natl. Acad. Sci. U. S. A. 87, 8612-8616.
20 Husson, A., Brasse-Lagnel, C., Fairand, A., Renouf, S., Lavoinne, A., 2003.
21 Argininosuccinate synthetase from the urea cycle to the citrulline–NO cycle. Eur.
22 J. Biochem. 270, 1887-1899.

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT

1 Igawa, T., Tani, T., Chijiwa, T., Shiragiku, T., Shimidzu, S., Kawamura, K., Kato, S.,
2 Unemi, F., Kimura, Y., 1990. Potentiation of anti-platelet aggregating activity of
3 cilostazol with vascular endothelial cells. Thromb. Res. 57, 617-623.
4 Ignarro, L.J., Buga, G.M., Wood, K.S., Byrns, R.E., Chaudhuri, G., 1987.
5 Endothelium-derived relaxing factor produced and released from artery and vein
6 is nitric oxide. Proc. Natl. Acad. Sci. U. S. A. 84, 9265-9269.
7 Jaffe, E.A., Hoyer, L.W., Nachman, R.L., 1973. Synthesis of antihemophilic factor
8 antigen by cultured human endothelial cells. J. Clin. Invest. 52, 2757-2764.
9 Kanno, K., Hirata, Y., Emori, T., Ohta, K., Eguchi, S., Imai, T., Marumo, F., 1992.
10 L-arginine infusion induces hypotension and diuresis/natriuresis concomitant with
11 increased urinary excretion of nitrite/nitrate and cyclic GMP in humans. Clin. Exp.
12 Pharmacol. Physiol. 19, 619-625.
13 Kurata, M., Tanaka, K., Usami, M., 1997. Different roles of endothelium- derived
14 substances on inhibiting platelet aggregation in whole blood. Gen. Pharmacol. 28,
15 671-673.
16 Macdonald, P.S., Read, M.A., Dusting, G.J., 1988. Synergistic inhibition of platelet
17 aggregation by endothelium-derived relaxing factor and prostacyclin. Thromb. Res.
18 49, 437-449.
19 Marietta, M., Facchinetti, F., Neri, I., Piccinini, F., 1997. L-arginine infusion
20 decreases platelet aggregation through an introplatelet nitric oxide release. Thromb.
21 Res. 88, 229- 235.

ACCEPTED MANUSCRIPT

1 Mellgren, K., Mellgren, G., Lundin, S., Wennmalm, A., Wadenvik, H., 1998. Effect of
2 nitric oxide gas on platelets during open heart operations. Ann. Thorac. Surg. 65,
3 1335-1341.
4 Mikashima, H., Takehara, S., Muramoto, Y., Khomaru, T., Terasawa, M., Tahara, T.,
5 Maruyama, Y., 1987. An antagonistic activity of etizolam on platelet-activating
6 factor (PAF). In vitro effects on platelet aggregation and PAF receptor binding. Jpn.
7 J. Pharmacol. 44, 387-391.
8 Radomski, M.W., Palmer, R.M., Moncada, S., 1987. The anti-aggregating properties
9 of vascular endothelium: interactions between prostacyclin and nitric oxide. Br. J.
10 Pharmacol. 92, 639-646.
11 Radomski, M.W., Palmer, R.M., Moncada, S., 1990. Characterization of the
12 l-arginine:nitric oxide pathway in human platelets, Br. J. Pharmacol. 101,
13 325-328.
14 Radomski, M.W., Vallance, P., Whitley, G., Foxwell, N., Moncada, S., 1993. Platelet
15 adhesion to human vascular endothelium is modulated by constitutive and
16 cytokine induced nitric oxide. Cardiovasc. Res. 27, 1380-1382.
17 Ratner, S., Petrack, B., 1951. Biosynthesis of urea. III. Further studies on arginine
18 synthesis from citrulline. J. Biol. Chem. 191, 693-705.
19 Sobrevia, L., Yudilevich, D.L., Mann, G.E., 1998. Elevated D-glucose induces insulin
20 insensitivity in human umbilical endothelial cells isolated from gestational
21 diabetic pregnancies. J. Physiol. 506, 219-230.
22 Su, Y., Block, E.R., 1995. Hypoxia inhibits L-arginine synthesis from L-citrulline in

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT

1 porcine pulmonary artery endothelial cells. Am. J. Physiol. 269, L581-587.
2 Tang, Z.Y., Wang, Y., Xiao, Y., Zhao, M., Peng, S., 2003. Anti-thrombotic activity of
3 PDR, a newly synthesized L-Arg derivative, on three thrombosis models in rats.
4 Thromb. Res. 110, 127-133.
5 Towbin, H., Staehelin, T., Gordon, J., 1979. Electrophoretic transfer of proteins from
6 polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
7 Proc. Natl. Acad. Sci. U. S. A. 76, 4350-4354.
8 Visek, W.J., 1986. Arginine needs, physiological state and usual diets. J. Nutr. 116,
9 36-46.
10 Wang, Y.Y., Tang, Z.Y., Dong, M., Liu, X.Y., Peng, S.Q., 2004. Inhibition of platelet
11 aggregation by polyaspartoyl L-arginine and its mechanism. Acta. Pharmacol. Sin.
12 25, 469-473.
13 Wu, G., Meininger, C.J., 1993. Regulation of L-arginine synthesis from L-citrulline
14 by L-glutamine in endothelial cells. *Am. J. Physiol*. 265, H1965-1971.
15 Xie, L., Gross, S.S., 1997. Argininosuccinate synthetase overexpression in vascular
16 smooth muscle cells potentiates immunostimulant-induced NO production. J. Biol.
17 Chem. 272, 16624-16630.

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT

1
2
3 Table 1 Effects of PDR on platelet aggregation and NO level in platelet reactants with or without
4 endothelial cells presence *in vitro* and the influence of NO synthase inhibitor L-NAME
5 (mean±SD, n=6).

Groups	Inhibitio % Platelet aggregation			Nitrites (nmol//L)		
	EC(-)	EC(+)	EC+L-NAME	EC(-)	EC(+)	EC+L-NAME
Vehicle control	0±13.0	5.3±14.3	-6.2±27.1	41.0±20.8	43.9±15.4	37.0±21.0
PDR(μg/ml) 1.7	2.0±6.5	36.4±11.8 [b, d]	6.8±8.0	40.9±30.5	108.2±13.4 [b d]	57.0±19.5
17	-1.8±11.1	50.4±10.1 [b d]	12.9±8.2	46.8±25.2	125.9±16.2 [b d]	61.1±24.8
170	4.0±13.7	65.3±9.2 [b d]	31.1±10.2 [a]	45.2±30.0	145.7±19.1 [b d]	77.4±15.5
L-Arginine 170	8.8±11.2	34.2±9.9 [b d]	-1.5±.15.8	48.2±29.7	90.8±15.6 [a c]	35.2±14.0
SNP 10μ M	82.8±9.8 [b]	88.8±11.3 [b]	79.0±9.7 [b]	339.8±64.1 [b]	321.9±94.0 [b]	334.7±24.2 [b]

6 EC（-）: platelets without endothelial cells

7 EC（+）: platelets with endothelial cells

8 EC+L-NAME: platelets with endothelial cells plus L-NAME
9 [a]*P*<0.05, [b]*P*<0.01 compared *vs* vehicle control of the same treatment;
10 [c]*P*<0.05, [d]*P*<0.01 compared *vs* the corresponding treated group without RAEC.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT

1
2



3
4



5
6

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT



1

2 Figure.1 The effects of PDR on intracellular amino acids level in cultured rat aortic
3 endothelial cells (RAEC). The cells were pretreated with vehicle (Control), with
4 succinate (+ succinate) for 30 min or with L-NAME (+L-NAME) for 24 h, and then
5 were treated with vehicle or agents(μg/ml) for 30 min at 37℃. L-arginine,
6 L-citrulliune and L-aspartate in RAEC extracts were determined by HPLC
7 respectively, and expressed as a percentage based on the mean value of vehicle group
8 in the control, which was set at 100% (mean±S.D., n=3). Panel A, B, C represented
9 the L-arginine level, L-citrulliune level and L-aspartate level respectively. $^{*}P<0.05$;
10 $^{**}P<0.01$ compared *vs* the intracellular amino acid of vehicle in the same set: $^{+}P<0.05$;
11 $^{++}P<0.01$ compared *vs* intracellular amino acid of the same treated group in the
12 control set.

13
14
15
16
17
18
19
20

ACCEPTED MANUSCRIPT

1
2
3
4



5

6 Figure 2. The effects on NO level in cultured medium in rat aortic endothelial cells .
7 The cells were pretreated with vehicle (set 1), succinate (set 2) or L-NAME (set 3),
8 and then were treated with vehicle or agents (μM) as described in Fig 3. The culture
9 mediums were saved for NO measurement. Contents of nitrite were used to express
10 the NO levels in the supernatants. Values are expressed as mean±SD (n=3), $^{*}P<0.05$;
11 $^{**}P<0.01$ compared *vs* the nitrite of vehicle in the same set. $^{+}P<0.05$; $^{++}P<0.01$
12 compared *vs* the nitrite of the corresponding treated in control set.

13
14
15
16
17
18
19
20
21
22
23
24

ACCEPTED MANUSCRIPT

ACCEPTED MANUSCRIPT



Figure 3 Effect of PDR on ASS protein expression in cultured rat aortic endothelial cells. The cells were treated with PDR for the indicated periods and the cell extracts were subjected to Western blot analysis. A) The shown was one result of 3 separate Western blot experiments. Line 1 was loaded with liver extracts (2 μg of protein) as the ASS marker, Line 2-5 were loaded extracts (50μg of protein) of cells. The bands of ASS and β-actin were identified using an anti-ASS mouse polyclonal antibody (1:1000) and an anti-actin mouse monoclonal antibody (1:1000), in which β-actin was used as a housekeeper. B) The statistic analysis results of ratio of ASS compared to β-actin were depicted as mean±S.D. (n=3), * $P<0.05$ *vs* vehiche groups.